Durvalumab 120 mg/4 mL, 500 mg/10 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 120 mg/4 mL, 500 mg/10 mL
Reference Brands: Imfinzi® (US & EU)
Category: Oncology Cancer Care
Durvalumab (Imfinzi®) is a PD-L1 checkpoint inhibitor used for urothelial carcinoma and NSCLC treatment. Available as sterile intravenous infusion vials (120 mg/4 mL, 500 mg/10 mL), it complies with EU-GMP and USFDA standards. Offered for B2B supply, hospital tenders, and licensing in regulated markets.
Product Description:
Durvalumab (Imfinzi®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma and non-small cell lung cancer. Provided as sterile intravenous infusion vials (120 mg/4 mL and 500 mg/10 mL), Durvalumab is manufactured under EU-GMP and USFDA standards. Available for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody enhances anti-tumor immunity by blocking PD-L1, making it a critical drug in immuno-oncology portfolios across the US and European markets.
Durvalumab — third party manufacturing & bulk supply
Durvalumab 120 mg/4 mL, 500 mg/10 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Durvalumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Durvalumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Durvalumab is used to treat certain types of cancer, including unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy and extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. It is also indicated for advanced or metastatic urothelial carcinoma. Durvalumab works by helping the immune system detect and attack cancer cells more effectively.
Durvalumab is a fully human monoclonal antibody made using recombinant DNA technology. It specifically targets and blocks the programmed death-ligand 1 (PD-L1) protein on cancer cells, which allows T cells to recognize and destroy these cells. The active ingredient is Durvalumab, and inactive components include histidine, sucrose, polysorbate 80, and water for injection.
The trade name of Durvalumab is Imfinzi.
Durvalumab is developed and manufactured by AstraZeneca Pharmaceuticals LP, a leading global biopharmaceutical company headquartered in the United Kingdom.
The generic name of the product is Durvalumab.
The brand name of the product is Imfinzi.
Durvalumab (Imfinzi) is manufactured by AstraZeneca at facilities located in the United Kingdom and the United States, and it is also produced in other AstraZeneca manufacturing sites in Europe to meet global demand.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
